

## IL36RN

## Recombinant Human Interleukin-36 Receptor Antagonist

<b>Catalog No.</b>	CS480A CS480B CS480C	<b>Quantity:</b>	2 µg 10 µg 1 mg
<b>Alternate Names:</b>	FIL1, FIL1(DELTA), FIL1D, IL1F5, IL1HY1, IL1L1, IL1RP3, IL36RA, PSORP		
<b>Description:</b>	<p>Interleukin-36 receptor antagonist (IL-36RA) is a secreted protein which belongs to the interleukin 1 cytokine family (IL-1 family) and it is predominantly expressed in keratinocytes but not in fibroblasts, endothelial cells or melanocytes. IL-36RA has been reported to antagonize the biological activity of IL-36alpha (IL-1F6), IL-36beta (IL-1F8), and IL-36gamma (IL-1F9). Furthermore, it could constitute part of an independent signaling system analogous to interleukin-1 alpha (IL-1A), beta (IL-1B) receptor agonist and interleukin-1 receptor type I (IL-1R1). In addition, the receptor for IL-36RA has not been positively identified, but it may be IL-1Rrp2.</p> <p>Recombinant Human IL-36RA is a single non-glycosylated polypeptide containing 154 amino acid residues. It shares 91 % a.a. sequence identity with mouse IL-36RA.</p>		
<b>Gene ID:</b>	26525		
<b>Source:</b>	<i>E. coli</i>		
<b>Molecular Weight:</b>	16.8 kDa		
<b>Formulation:</b>	Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4, + 5 mM beta-mercaptoethanol.		
<b>Purity:</b>	>95 % by SDS-PAGE and HPLC analyses.		
<b>Endotoxin Level:</b>	<1 EU/µg of IL-36RA as determined by LAL method.		
<b>Biological Activity:</b>	Fully biologically active as compared to standard. The ED <sub>50</sub> determined by inhibiting IL-36 beta induced IL-8 secretion by human preadipocytes is <1.25 µg/ml.		
<b>Specific Activity:</b>	>800 IU/mg in the presence of 20 ng/ml of recombinant human IL-36 beta.		
<b>Amino Acid Sequence:</b>	VLSGALCFRM KDSALKVLYL HNNQLLAGGL HAGKVIK GEE ISVVPNRWLD ASLSPVILGV QGGSQCLSCG VGQEPTLTLE PVNIMELYLG AKESKSFTFY RRDMLTSSSF ESAAYPGWFL CTVPEADQPV RLTQLPENGW WNAIPITDFYF QQCD		
<b>Reconstitution:</b>	<b>Centrifuge vial prior to opening.</b> Add sterile distilled water or aqueous buffer to a concentration of 0.1-1.0 mg/mL. Further dilutions should be made in appropriate buffered solutions.		
<b>Storage &amp; Stability:</b>	This lyophilized preparation is stable at 2-4°C, but should be kept desiccated at -20°C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2 -4° C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -80°C. <b>Avoid repeated freeze/thaw cycles.</b>		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.